176 related articles for article (PubMed ID: 1583784)
21. Epithelial ovarian tumors in the reproductive age group: age is not an independent prognostic factor.
Massi D; Susini T; Savino L; Boddi V; Amunni G; Colafranceschi M
Cancer; 1996 Mar; 77(6):1131-6. PubMed ID: 8635134
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms.
Henriksen R; Funa K; Wilander E; Bäckström T; Ridderheim M; Oberg K
Cancer Res; 1993 Oct; 53(19):4550-4. PubMed ID: 8402626
[TBL] [Abstract][Full Text] [Related]
23. [Borderline ovarian tumors. Retrospective analysis of 20 cases].
Iervolino P; Palmieri M; Rotondi M; D'Alessandro P; Iuliano R
Minerva Ginecol; 2001 Feb; 53(1 Suppl 1):97-9. PubMed ID: 11526732
[TBL] [Abstract][Full Text] [Related]
24. Human telomerase reverse transcriptase expression in ovarian tumors.
Maraei AA; Hatta AZ; Shiran MS; Tan GC
Indian J Pathol Microbiol; 2012; 55(2):187-91. PubMed ID: 22771641
[TBL] [Abstract][Full Text] [Related]
25. Proliferative activity and p53 over-expression of ovarian epithelial tumors.
Kuwata T; Kitagawa M; Takemura T; Hirokawa K
Gen Diagn Pathol; 1995 Oct; 141(2):131-9. PubMed ID: 8548593
[TBL] [Abstract][Full Text] [Related]
26. Ovarian mucinous borderline tumors of intestinal type without intraepithelial carcinoma: are they still tumors of low malignant potential?
Nomura K; Aizawa S; Hano H
Pathol Int; 2004 Jun; 54(6):420-4. PubMed ID: 15144401
[TBL] [Abstract][Full Text] [Related]
27. Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms.
Sainz de la Cuesta R; Goff BA; Fuller AF; Nikrui N; Eichhorn JH; Rice LW
Obstet Gynecol; 1994 Jul; 84(1):1-7. PubMed ID: 8008300
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
29. Increased staining for phosphorylated AKT and nuclear factor-kappaB p65 and their relationship with prognosis in epithelial ovarian cancer.
Guo RX; Qiao YH; Zhou Y; Li LX; Shi HR; Chen KS
Pathol Int; 2008 Dec; 58(12):749-56. PubMed ID: 19067848
[TBL] [Abstract][Full Text] [Related]
30. Chromosome 6 abnormalities in ovarian surface epithelial tumors of borderline malignancy suggest a genetic continuum in the progression model of ovarian neoplasms.
Tibiletti MG; Bernasconi B; Furlan D; Bressan P; Cerutti R; Facco C; Franchi M; Riva C; Cinquetti R; Capella C; Taramelli R
Clin Cancer Res; 2001 Nov; 7(11):3404-9. PubMed ID: 11705855
[TBL] [Abstract][Full Text] [Related]
31. [Serous and mucinous ovarian cystadenomas at the limit of malignancy].
Chenevart P; Gloor E
Schweiz Med Wochenschr; 1980 Apr; 110(14):531-9. PubMed ID: 7375903
[TBL] [Abstract][Full Text] [Related]
32. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
Gao GL; Liu LD; Zou XS; Chen WX
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
[TBL] [Abstract][Full Text] [Related]
33. Borderline tumors of the ovary and peritoneal implants.
Denkert C; Dietel M
Verh Dtsch Ges Pathol; 2005; 89():84-91. PubMed ID: 18035677
[TBL] [Abstract][Full Text] [Related]
34. Conservative surgery for borderline ovarian tumors: a review.
Tinelli R; Tinelli A; Tinelli FG; Cicinelli E; Malvasi A
Gynecol Oncol; 2006 Jan; 100(1):185-91. PubMed ID: 16216320
[TBL] [Abstract][Full Text] [Related]
35. Expression of p57kip2 and its clinical relevance in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Anticancer Res; 2002; 22(6A):3191-6. PubMed ID: 12530064
[TBL] [Abstract][Full Text] [Related]
36. [Prognosis factors in epithelial tumors of the ovary].
Frigerio L; Ferrari A; Busci L; Pirondini A; Garsia S; Caldarella M; Pifarotti G
Ann Ostet Ginecol Med Perinat; 1989; 110(6):283-9. PubMed ID: 2639615
[TBL] [Abstract][Full Text] [Related]
37. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors.
Berchuck A; Kohler MF; Hopkins MP; Humphrey PA; Robboy SJ; Rodriguez GC; Soper JT; Clarke-Pearson DL; Bast RC
Gynecol Oncol; 1994 Feb; 52(2):232-6. PubMed ID: 7508877
[TBL] [Abstract][Full Text] [Related]
39. Nuclear deoxyribonucleic acid heterogeneity of ovarian borderline malignant serous tumors.
Fu YS; Ro J; Reagan JW; Hall TL; Berek J
Obstet Gynecol; 1986 Apr; 67(4):478-82. PubMed ID: 3960418
[TBL] [Abstract][Full Text] [Related]
40. Ki-67 immunostaining and DNA flow cytometry as prognostic factors in epithelial ovarian cancers.
Henriksen R; Strang P; Backstrom T; Wilander E; Tribukait B; Oberg K
Anticancer Res; 1994; 14(2B):603-8. PubMed ID: 8010717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
